A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

EDGe Surgical Receives CE Mark Certification for EDG® Ortho 65mm Electronic Depth Gauge

EDGe Surgical, Inc., develops and manufactures smart orthopedic and spine surgical instruments. Today they announced they have received a CE Certificate of Conformity from its notified body permitting CE mark of the company’s EDG® Ortho 65mm single-use electronic depth gauge in the European Union market.

“This is a great achievement for EDGe Surgical on several levels,” said Christopher Wilson, CEO, EDGe Surgical, Inc. “The approval enables us to gain access to markets that accept CE-marked medical devices, and it also sets the stage for strategic partnerships with larger manufacturers who are not ready to transition to the new EU Medical Device Regulation (MDR) that goes into effect later this month.”

Under the MDR, traditional metal depth gauges will be reclassified to a higher, riskier classification and must be certified by a “notified body” instead of self-certification by the manufacturer. Notified bodies are organizations designated by an EU country to assess the conformity of certain products before being placed on the market.

“Preparing for the requirements under the new MDR is placing significant resource strain on large orthopedic manufacturers, and some have made the tough decision to discontinue certain products due to lack of readiness,” Wilson continued. “Our EDG Ortho electronic depth gauge is a readily available option for manufacturers that are having difficulty transitioning their legacy metal depth gauges to the more stringent requirements.”

The EDG Ortho is a sterile, single-use device used to more accurately and safely measure which length screw should be implanted into a patient during orthopedic fracture surgeries.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy